ICER's analysis is slated to include two as-yet unapproved monoclonal antibody treatments, donanemab and lecanemab, as well as Aduhelm (aducanumab).
A final evidence report is scheduled to come out on Aug. 15
When the FDA approved Biogen’s controversial Alzheimer’s drug, Aduhelm (aducanumab), in June 2021, the Institute for Clinical and Economic Review (ICER) joined the chorus of criticism.
The cost-effectiveness group issued a statement that said that the FDA “has failed in its responsibility to protect patients and families from unproven treatments with known harms.” Two months later, ICER came out with a pricing report that said the drug should be priced between $2,500 and $8,300 per year, which was far below the initial price of about $56,000 a year. Biogen announced in December that it was halving the price.
This year, ICER has Aduhelm in its sights again although this time the organization is comparing it with two other monoclonal antibodies that target the clumps of beta amyloid in the brain that many experts believe are the main cause of Alzheimer’s.
The two other monoclonal antibodies included in ICER’s review are Eli Lilly’s donanemab and Eisai's lecanemab. The companies submitted applications for FDA approval of both agents late last year, and the regulatory agency is scheduled to make a decision on whether to approve them this year.
According to a timeline on its website, ICER is accepting public comments on its scoping document for the three-drug review through Jan. 19. A draft evidence report is scheduled to come out May 10 andon August 15.
Get the latest industry news, event updates, and more from Managed healthcare Executive.
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 25th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
FDA Extends Review of Blenrep Combinations in Multiple Myeloma
July 24th 2025Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing and tolerability. The new action date is Oct. 23, 2025.
Read More
Sarepta to Pause Shipments of the Gene Therapy Elevidys
July 22nd 2025Sarepta officials said the temporary halt in shipments was done to maintain a productive working relationship with regulators while they address a safety labeling update about the risk of acute liver disease related to Elevidys.
Read More